DESIGN: A007 is a randomized, two-arm study evaluating the effectiveness of standard drug addiction counseling with buprenorphine/naloxone to enhanced motivational drug counseling with buprenorphine/naloxone for the treatment for opioid addiction in an integrated and nonintegrated HIV care setting.~DURATION: Subjects will participate in this study for approximately 48 weeks. Chart abstractions will continue for up to four years.~SAMPLE SIZE: This study will enroll 60 subjects (30 per arm) over 72 weeks.~POPULATION: HIV-1 infected opioid dependent men and women ≥18 years of age who initiate buprenorphine for the treatment of opioid dependence and who are receiving primary care for HIV-1 infection.~STRATIFICATION: Subjects will be stratified at screening based on HIV care setting (integrated HIV care vs. nonintegrated HIV care)~INTERVENTON At entry subjects will be randomized to one of the following:~ARM A: Standard drug addiction counseling + buprenorphine / naloxone~ARM B: Enhanced behavioral motivation counseling + buprenorphine / naloxone~The three primary outcomes are:~Cessation of illicit opioid use~Reduction in high risk behavior~Improved HIV therapy adherence
A007 is a randomized, two-arm study evaluating the effectiveness of standard drug addiction counseling with buprenorphine/naloxone to enhanced motivational drug counseling with buprenorphine/naloxone for the treatment for opioid addiction in an integrated and nonintegrated HIV care setting.